Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000777796
Ethics application status
Approved
Date submitted
10/07/2013
Date registered
11/07/2013
Date last updated
19/09/2019
Date data sharing statement initially provided
19/09/2019
Date results information initially provided
19/09/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase II Extension study to assess the safety and tolerability of PBT2 and its effect on amyloid levels in the brains of patients with prodromal or mild Alzheimer's disease.
Scientific title
An Open Label Extension Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease.
Secondary ID [1] 282731 0
Nil
Universal Trial Number (UTN)
Trial acronym
PBT2-204-Ext
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prodromal Alzheimer's disease or mild Alzheimer's disease 289465 0
Condition category
Condition code
Mental Health 289777 289777 0 0
Other mental health disorders
Neurological 289778 289778 0 0
Alzheimer's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
PBT2 is supplied as 250mg immediate-release capsules. The dose for this study is 250mg / day ie. one capsule is to be taken orally, once a day for 52 weeks duration.
Information on compliance will be collected via a Diary Card and accountability of drug returns. It is also the role of the Study Partner to over-see the daily taking of study drug.
Intervention code [1] 287394 0
Treatment: Drugs
Comparator / control treatment
Nil
Control group
Uncontrolled

Outcomes
Primary outcome [1] 289861 0
To evaluate the safety and tolerability of PBT2 after 52 weeks of treatment as measured by capture of vital signs, physical examination, neurological examination, ECG, eye examination, blood haematology and biochemistry, urinalysis and recording of adverse events.
Possible side effects include tiredness, headache, dizziness, nasopharyingitis and drowsiness.
Timepoint [1] 289861 0
Baseline, 4, 8, 13, 26, 39 and 52 weeks after commencement of treatment with PBT2 and 4 weeks after cessation of treatment with PBT2
Primary outcome [2] 289862 0
To evaluate the effect of PBT2 on brain amyloid levels after 52 weeks of treatment as measured by Carbon 11-Pittsburgh Imaging Compound-B (PiB) Positron Emission Tomography (PET) imaging.
Timepoint [2] 289862 0
52 weeks after commencement of treatment with PBT2.
Secondary outcome [1] 303405 0
To evaluate the effect of PBT2 on brain metabolic activity after 52 weeks as measured by Fluorine 18 labelled Fluorodeoxyglucose (FDG) PET imaging.
Timepoint [1] 303405 0
52 weeks after commencement of treatment with PBT2.
Secondary outcome [2] 303406 0
To evaluate the effect of PBT2 on brain volumes after 52 weeks as assessed by Magnetic Resonance Imaging (MRI) to measure the cortical grey matter volume, hippocampal volume and ventricular volume.
Timepoint [2] 303406 0
52 weeks after commencement of treatment with PBT2.
Secondary outcome [3] 303407 0
To evaluate the effect of PBT2 on cognition after 52 weeks as measured by a Neuropsychological Test Battery (NTB) questionnaires and the Mini-mental State Examination (MMSE) questionnaire.
Timepoint [3] 303407 0
Baseline, 26 and 52 weeks after commencement of treatment with PBT2.
Secondary outcome [4] 303408 0
To evaluate the effect of PBT2 on functional ability after 52 weeks as measured by the Alzheimer's disease Cooperative Study-Activities of Daily Living-23 (ADCS-ADL-23) questionnaire
Timepoint [4] 303408 0
Baseline and 52 weeks after commencement of treatment with PBT2.
Secondary outcome [5] 303409 0
To evaluate the effect of PBT2 on Alzheimer's disease blood biomarkers.
Timepoint [5] 303409 0
Baseline, 13, 26, 39 and 52 weeks after commencement of treatment with PBT2 and 1 month after cessation of treatment.

Eligibility
Key inclusion criteria
1. Patients who have completed Visit 10 (Week 52) of the PBT2-204 (IMAGINE) clinical trial [ACTRN12611001008910].
Minimum age
55 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Allergy to PBT2 or its excipients (microcrystalline cellulose, pregelatinised starch, colloidal silicon dioxide, povidone K29/32 and sodium stearyl fumurate).
2. Have developed any clinically significant uncontrolled medical, ocular or psychiatric illness during PBT2-204.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All participants enrolled into this Extension study will receive PBT2, regardless of their treatment allocation in the IMAGINE (PBT2-204) clinical trial.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
25/07/2013
Actual
24/07/2013
Date of last participant enrolment
Anticipated
31/12/2013
Actual
3/12/2013
Date of last data collection
Anticipated
Actual
8/01/2015
Sample size
Target
40
Accrual to date
Final
33
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 1207 0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg West
Recruitment hospital [2] 1209 0
Delmont Private Hospital - Glen Iris
Recruitment hospital [3] 1210 0
Geelong Private Hospital - Geelong
Recruitment postcode(s) [1] 7069 0
3081 - Heidelberg West
Recruitment postcode(s) [2] 7071 0
3146 - Glen Iris
Recruitment postcode(s) [3] 7072 0
3220 - Geelong

Funding & Sponsors
Funding source category [1] 287559 0
Commercial sector/Industry
Name [1] 287559 0
Prana Biotechnology Ltd
Country [1] 287559 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Alterity Therapeutics
Address
Level 3, 460 Bourke Street, Melbourne, Victoria, 3000,
Country
Australia
Secondary sponsor category [1] 286310 0
None
Name [1] 286310 0
Address [1] 286310 0
Country [1] 286310 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 289536 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 289536 0
145 Studley Road
Heidelberg VIC 3084
Ethics committee country [1] 289536 0
Australia
Date submitted for ethics approval [1] 289536 0
03/06/2013
Approval date [1] 289536 0
02/07/2013
Ethics approval number [1] 289536 0
HREC/13/Austin/54

Summary
Brief summary
This is a Phase II Extension study to examine the safety, tolerability and effect of 52 weeks treatment with PBT2 in patients with prodromal or mild Alzheimer's disease (AD). The primary objectives are to examine the safety and tolerability and the effect of PBT2 on the amount of amyloid in patients brains after 52 weeks of treatment when measured by a particular type of brain scan, PiB-Positron Emission Tomography (PET). The effects of PBT2 on brain volume, brain metabolic activity, blood biomarkers of AD and cognition plus functional abilities will also be investigated.
Trial website
Trial related presentations / publications
The hyperlink to the trial publication is:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702880/
Public notes
Please note that participation in this Extension study is only open to patients who have participated in the PBT2-204 clinical trial. No new patients will be entered.

Contacts
Principal investigator
Name 41026 0
A/Prof Michael Woodward
Address 41026 0
Medical & Cognitive Research Unit Heidelberg Repatriation Hospital 300 Waterdale Road Heidelberg West, VIC 3081
Country 41026 0
Australia
Phone 41026 0
+61 (0)3 9496 2852
Fax 41026 0
Email 41026 0
[email protected]
Contact person for public queries
Name 41027 0
Ms Cynthia Wong
Address 41027 0
Alterity Therapeutics, 39899 Balentine Drive, Suite 360, Newark, CA 94560
Country 41027 0
United States of America
Phone 41027 0
+16503002141
Fax 41027 0
N/A
Email 41027 0
[email protected]
Contact person for scientific queries
Name 41028 0
Dr David Stamler
Address 41028 0
Alterity Therapeutics, 39899 Balentine Drive, Suite 360, Newark, CA 94560
Country 41028 0
United States of America
Phone 41028 0
+16503002141
Fax 41028 0
N/A
Email 41028 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Study results articleYes The hyperlink to the publication is: https://w... [More Details]

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIRedox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease2021https://doi.org/10.3390/ijms22147697
N.B. These documents automatically identified may not have been verified by the study sponsor.